Skip to content

Clinical trials

Cardiomyopathy, Hypertrophic trials with no applicable phase

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Cardiomyopathy, Hypertrophic Phase: Not applicable Clear all

81 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20061
20091
20102
20112
20122
20132
20143
20153
20164
20171
20186
20199
20206
20217
20224
20235
20247
20259
20267

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed26
Unknown status24
Recruiting10
Not yet recruiting8
Active, not recruiting6
Terminated5
Withdrawn2

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Meshalkin Research Institute of Pathology of Circulation5
Barts & The London NHS Trust4
Xijing Hospital4
China National Center for Cardiovascular Diseases3
Imperial College London3
Assiut University2
French Cardiology Society2
Hangzhou Valgen Medtech Co., Ltd2
National Heart, Lung, and Blood Institute (NHLBI)2
Oregon Health and Science University2

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Cardiomyopathy, Hypertrophic81
Cardiomyopathies7
Cardiomyopathy, Dilated6
Ventricular Outflow Obstruction, Left5
Atrial Fibrillation3
Heart Failure3
Aortic Valve Stenosis2
Cardiomyopathy, Restrictive2
Coronary Artery Disease2
Death, Sudden, Cardiac2

Trials

Showing 1 to 25 of 81. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.